Analysts Issue Forecasts for XFOR FY2027 Earnings

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR - Free Report) - Brookline Capital Management cut their FY2027 EPS estimates for X4 Pharmaceuticals in a research report issued on Thursday, February 6th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings of $0.36 per share for the year, down from their prior estimate of $0.42. The consensus estimate for X4 Pharmaceuticals' current full-year earnings is ($0.68) per share.

Several other research firms have also issued reports on XFOR. Stifel Nicolaus dropped their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a "buy" rating on the stock in a research report on Thursday, November 14th. HC Wainwright reissued a "buy" rating and set a $1.50 target price on shares of X4 Pharmaceuticals in a report on Friday, February 7th.

X4 Pharmaceuticals Stock Up 4.6 %

Shares of XFOR stock traded up $0.02 during trading on Monday, reaching $0.50. The company's stock had a trading volume of 1,239,044 shares, compared to its average volume of 5,764,367. The company has a market cap of $85.72 million, a price-to-earnings ratio of -5.58 and a beta of 0.12. The business has a fifty day moving average price of $0.60 and a 200-day moving average price of $0.59. The company has a quick ratio of 4.80, a current ratio of 4.89 and a debt-to-equity ratio of 1.26. X4 Pharmaceuticals has a one year low of $0.26 and a one year high of $1.60.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Verition Fund Management LLC purchased a new stake in shares of X4 Pharmaceuticals during the third quarter worth about $30,000. SG Americas Securities LLC purchased a new stake in X4 Pharmaceuticals during the 3rd quarter valued at $37,000. Atria Wealth Solutions Inc. bought a new stake in shares of X4 Pharmaceuticals in the fourth quarter worth approximately $44,000. Wells Fargo & Company MN lifted its holdings in X4 Pharmaceuticals by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 78,518 shares of the company's stock valued at $58,000 after acquiring an additional 26,763 shares during the period. Finally, XTX Topco Ltd boosted its holdings in shares of X4 Pharmaceuticals by 41.7% in the third quarter. XTX Topco Ltd now owns 157,642 shares of the company's stock worth $106,000 after buying an additional 46,397 shares during the last quarter. 72.03% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity at X4 Pharmaceuticals

In other news, CEO Paula Ragan sold 76,473 shares of the business's stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total transaction of $34,412.85. Following the completion of the sale, the chief executive officer now directly owns 1,087,386 shares of the company's stock, valued at $489,323.70. The trade was a 6.57 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Adam S. Mostafa sold 74,773 shares of the company's stock in a transaction dated Friday, January 24th. The stock was sold at an average price of $0.45, for a total transaction of $33,647.85. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock worth $91,198 over the last ninety days. Insiders own 1.62% of the company's stock.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.